Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

BMC Infectious Diseases, 05/07/2012

Considering the epidemiology of pneumococcal disease in Canada, PCV13 is shown to be a cost–saving immunization program because it provides substantial public health and economic benefits relative to PCV10.

Print Article Summary Cat 2 CME Report